- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono | 10 | FierceBiotech | ||
| 09.11. | Fate Therapeutics, Inc.: Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual ... | 60 | GlobeNewswire (Europe) | Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable... ► Artikel lesen | |
| 31.10. | Ono Pharmaceutical reports Q2 results | 16 | Seeking Alpha | ||
| 10.10. | Ono links with LigaChem to bag preclinical ADC in $700M biobuck deal | 2 | FierceBiotech | ||
| 10.10. | Ono, Boehringer add to cancer pipelines with licensing deals | 5 | pharmaphorum | ||
| 10.10. | Ligachem Biosciences Agrees to Transfer ADC Technology to Ono Pharmaceutical | 2 | BusinessKorea | ||
| 07.10. | Kinaxis Inc: Kinaxis provides supply chain management to Ono Pharma | 1 | Stockwatch | ||
| ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 07.10. | Kinaxis Inc.: Kinaxis unterstützt das Lieferkettenmanagement von Ono Pharmaceutical | 226 | Business Wire | Kinaxis stellt Plattform für die End-to-End-Lieferkettenorchestrierung zur Unterstützung des weiteren globalen Wachstums von Ono Pharmaceutical bereit Kinaxis Inc. (TSX:KXS), ein Weltmarktführer... ► Artikel lesen | |
| 01.10. | Shattuck axes CD47 program over weak efficacy data, lays off 40% of staff and loses Ono deal | 1 | FierceBiotech | ||
| 12.09. | Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical | 315 | Business Wire | - Turbine has successfully completed the first phase of its oncology target identification and validation collaboration with Ono - Ono's selection of multiple targets identified using Turbine's... ► Artikel lesen | |
| 30.08. | UBS downgrades Ono Pharmaceutical stock to sell, slashes price target | 16 | Investing.com | ||
| 31.07. | EQS-News: Systasy Bioscience GmbH: Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical | 286 | EQS Group (EN) | EQS-News: Systasy Bioscience GmbH
/ Key word(s): Agreement
Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical
31.07.2024 / 09:00 CET/CEST
The... ► Artikel lesen | |
| 12.06. | Ono Acquires Deciphera Pharmaceuticals | 10 | Contract Pharma | ||
| 11.06. | Ono Pharmaceutical completes tender offer for Deciphera | 10 | Seeking Alpha | ||
| 30.04. | Ono Pharmaceutical co., ltd.: ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals | 284 | PR Newswire | OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera... ► Artikel lesen | |
| 29.04. | Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion | 237 | Business Wire | WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve... ► Artikel lesen | |
| 14.03. | Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders | 400 | Business Wire | Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla's cutting-edge Pharmacological Protein Inactivation by Folding... ► Artikel lesen | |
| 14.02. | Ono Pharmaceutical co., ltd.: Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins | 232 | PR Newswire | OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration... ► Artikel lesen | |
| 14.02. | Numab Therapeutics AG: Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer | 563 | GlobeNewswire (Europe) | NM49 is a multi-specific antibody identified through Numab's proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis
Numab to receive... ► Artikel lesen | |
| 13.02. | Shattuck Labs, Inc.: Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases | 261 | GlobeNewswire (Europe) | AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 85,06 | +1,15 % | Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with... ► Artikel lesen | |
| CANOPY GROWTH | 3,785 | +6,17 % | Jetzt wird es brenzlig: Kurse von Tilray, Canopy & Co. brechen massiv ein. So heftig könnte es werden | © Foto: Piyapong Thongdumhyu - 123rf StockfotoRund um die US-Wahl fielen weitere Entscheidungen. Während der Cannabis-Sektor die Wahl Trumps zum nächsten US-Präsidenten noch nicht so ganz einordnen... ► Artikel lesen | |
| MERCK & CO | 94,80 | +2,49 % | Merck & Co., Inc.: Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care | RAHWAY, NJ / ACCESSWIRE / November 20, 2024 / The Merck Foundation (Foundation) has announced a new initiative to help advance equitable access to high-quality, culturally responsive care for people... ► Artikel lesen | |
| JAGUAR HEALTH | 0,965 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Family Company Napo Therapeutics Named "Best Pharmaceuticals Innovator of the Year - Europe" | Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN... ► Artikel lesen | |
| IQVIA | 183,65 | -0,43 % | (IQV) - Analyzing IQVIA Holdings' Short Interest | ||
| MADRIGAL PHARMACEUTICALS | 305,30 | +1,39 % | Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra | ||
| AZENTA | 43,200 | +1,89 % | S&P Dow Jones Indices: Flex Ltd. Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600 | NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:
Flex Ltd (NASD: FLEX)... ► Artikel lesen | |
| PROTHENA | 13,400 | -2,19 % | Prothena Corporation plc: Prothena Reports Third Quarter 2024 Financial Results and Business Highlights | Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash... ► Artikel lesen | |
| ALMIRALL | 8,220 | -1,20 % | Almirall, S.A.: Almirall's Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth | Positive growth trajectory maintained with Net Sales increase of 7.9% to a total of €727.6 MM, EBITDA of €142.2 MM (+2.9% YoY) driven by increased overall sales and strong performance of the... ► Artikel lesen | |
| PETIQ | 28,400 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 28.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.10.2024ISIN NameCA6882811046 OSISKO... ► Artikel lesen | |
| FUJI PHARMA | 8,400 | -2,89 % | Dividendenbekanntmachungen (27.09.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN EUROPEAN LOGISTICS INCOME PLC GB00BD9PXH49 0,0077 GBP EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1926 EUR ACOM CO LTD JP3108600002 7... ► Artikel lesen | |
| FINANCIERE DE TUBIZE | 129,60 | +2,05 % | Financière de Tubize SA: Financière de Tubize - Transparency notification | Publication concerning a transparency notification(article 14, first paragraph of the law of 2 May 2007 concerning the publication of significant participating interests)
Press release - Regulated... ► Artikel lesen | |
| BAYER | 19,518 | -0,13 % | Daimler-Truck, dynaCERT, Bayer AG: Gegensätze im 3. Quartal: Etablierte unter Druck, Newcomer mit Durchbruch | Etablierte DAX-Konzerne wie die Bayer AG und Daimler Truck, ein Unternehmen der Mercedes-Benz Gruppe, kämpfen im dritten Quartal 2024 mit Gegenwind. Doch der kanadische Cleantech-Spezialist dynaCERT... ► Artikel lesen | |
| MERCK KGAA | 138,30 | +0,14 % | Merck Aktie: Was kommt? | ||
| GSK | 15,875 | +0,41 % | Dividendenbekanntmachungen (14.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PROPERTY INCOME TRUST LIMITED GB0033875286 0,003 GBP 0,0036 EUR AFFILIATED MANAGERS GROUP INC US0082521081 0,01 USD 0,0094... ► Artikel lesen |
ONO PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONO PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.
